Ratings by Guggenheim (Yatin Suneja)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/31/2022 | Bausch & Lomb Corp. | BLCO | New Coverage | Buy (N/A) |
17.69 (15.85) |
-10.4% | Details | |
| 5/9/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2022 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2022 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2022 | Global Blood Therapeutics | GBT | Maintain | Buy (N/A) |
|
Details | ||
| 5/5/2022 | EyePoint Pharmaceuticals, Inc. | EYPT | Maintain | Buy (N/A) |
|
Details | ||
| 4/25/2022 | Eliem Therapeutics Inc. | ELYM | Downgrade | Neutral (Buy) |
6.51 (3.65) |
-43.93% | Details | |
| 4/7/2022 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 3/22/2022 | AnaptysBio | ANAB | Downgrade | Neutral (Buy) |
26.50 (23.12) |
-12.75% | Details | |
| 3/2/2022 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (N/A) |
|
Details | ||
| 3/2/2022 | Horizon Therapeutics | HZNP | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2022 | Inflarx NV | IFRX | Downgrade | Neutral (Buy) |
3.01 (0.78) |
-74.09% | Details | |
| 2/22/2022 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 2/1/2022 | Vigil Neuroscience Inc | VIGL | New Coverage | Buy (N/A) |
12.90 (2.91) |
-77.44% | Details | |
| 1/19/2022 | Zogenix, Inc. | ZGNX | Downgrade | Neutral (Buy) |
15.64 (26.68) |
70.59% | Details | |
| 1/13/2022 | Biogen | BIIB | Downgrade | Neutral (Buy) |
225.34 (211.93) |
-5.95% | Details | |
| 12/21/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Neutral (Buy) |
27.09 (14.98) |
-44.7% | Details | |
| 11/2/2021 | Sage Therapeutics | SAGE | Upgrade | Buy (Neutral) |
42.37 (33.65) |
-20.58% | Details | |
| 11/1/2021 | Acadia Pharmaceuticals | ACAD | Upgrade | Buy (Neutral) |
17.95 (14.98) |
-16.55% | Details | |
| 10/29/2021 | argenx SE | ARGX | Upgrade | Buy (Neutral) |
279.58 (364.35) |
30.32% | Details | |
| 10/25/2021 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 10/18/2021 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (N/A) |
|
Details | ||
| 10/4/2021 | Xenon Pharmaceuticals | XENE | Maintain | Buy (N/A) |
|
Details | ||
| 9/15/2021 | Surrozen Inc. | SRZN | New Coverage | Buy (N/A) |
10.13 (3.43) |
-66.14% | Details | |
| 9/7/2021 | Eliem Therapeutics Inc. | ELYM | New Coverage | Buy (N/A) |
27.56 (3.65) |
-86.76% | Details | |
| 8/10/2021 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 7/22/2021 | Celldex Therapeutics | CLDX | New Coverage | Buy (N/A) |
43.30 (29.35) |
-32.22% | Details | |
| 7/1/2021 | Seelos Therapeutics | SEEL | New Coverage | Buy (N/A) |
2.64 (0.66) |
-75% | Details | |
| 6/21/2021 | Orphazyme | ORPH | Downgrade | Buy (Sell) |
7.33 (0.87) |
-88.13% | Details | |
| 6/15/2021 | Sage Therapeutics | SAGE | Downgrade | Neutral (Buy) |
72.86 (42.37) |
-41.85% | Details | |
| 6/9/2021 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 6/1/2021 | Immunovant | IMVT | Downgrade | Neutral (Buy) |
15.16 (4.17) |
-72.49% | Details | |
| 4/23/2021 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 3/18/2021 | Phathom Pharmaceuticals | PHAT | Maintain | Buy (N/A) |
|
Details | ||
| 3/11/2021 | Inflarx NV | IFRX | Upgrade | Buy (N/A) |
4.30 (0.78) |
-81.86% | Details | |
| 3/9/2021 | Acadia Pharmaceuticals | ACAD | Downgrade | Neutral (Buy) |
45.78 (14.98) |
-67.28% | Details | |
| 2/2/2021 | Phathom Pharmaceuticals | PHAT | New Coverage | Buy (N/A) |
38.50 (8.59) |
-77.69% | Details | |
| 1/4/2021 | Sage Therapeutics | SAGE | Upgrade | Buy (Neutral) |
86.51 (72.86) |
-15.78% | Details | |
| 11/4/2020 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 10/26/2020 | Orphazyme | ORPH | New Coverage | Buy (N/A) |
10.07 (0.87) |
-91.36% | Details | |
| 10/14/2020 | AnaptysBio | ANAB | Upgrade | Buy (Neutral) |
17.76 (23.12) |
30.18% | Details | |
| 8/18/2020 | Principia Biopharma | PRNB | Downgrade | Neutral (Buy) |
99.25 (100.05) |
0.81% | Details | |
| 8/17/2020 | BioXcel Therapeutics | BTAI | Maintain | Buy (N/A) |
|
Details | ||
| 8/17/2020 | Arena Pharma | ARNA | Maintain | Buy (N/A) |
|
Details | ||
| 7/8/2020 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 7/6/2020 | Principia Biopharma | PRNB | New Coverage | Buy (N/A) |
56.00 (99.25) |
77.23% | Details | |
| 6/4/2020 | BioXcel Therapeutics | BTAI | New Coverage | Buy (N/A) |
45.14 (12.11) |
-73.17% | Details | |
| 5/26/2020 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 4/27/2020 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 4/8/2020 | Sage Therapeutics | SAGE | Downgrade | Neutral (Buy) |
29.03 (33.65) |
15.91% | Details | |
| 3/19/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 2/28/2020 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 2/27/2020 | Acadia Pharmaceuticals | ACAD | Maintain | Buy (N/A) |
|
Details | ||
| 2/26/2020 | GW Pharma | GWPH | Maintain | Buy (N/A) |
|
Details | ||
| 2/24/2020 | argenx SE | ARGX | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2020 | Biogen | BIIB | Maintain | Buy (N/A) |
|
Details | ||
| 2/11/2020 | Regeneron Pharma | REGN | Maintain | Buy (N/A) |
|
Details | ||
| 2/7/2020 | Zogenix, Inc. | ZGNX | Maintain | Neutral (N/A) |
|
Details | ||
| 1/27/2020 | Global Blood Therapeutics | GBT | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2019 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 12/16/2019 | Acadia Pharmaceuticals | ACAD | New Coverage | Buy (N/A) |
44.34 (14.98) |
-66.22% | Details | |
| 12/16/2019 | Relmada Therapeutics Inc | RLMD | New Coverage | Buy (N/A) |
34.14 (19.65) |
-42.44% | Details | |
| 12/5/2019 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 12/4/2019 | Axsome Therapeutics | AXSM | Maintain | Buy (N/A) |
|
Details | ||
| 11/20/2019 | Exicure | XCUR | New Coverage | Buy (N/A) |
2.60 (0.13) |
-95% | Details | |
| 11/15/2019 | resTORbio Inc. | TORC | Downgrade | Neutral (Buy) |
7.95 (2.28) |
-71.32% | Details | |
| 11/13/2019 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 11/8/2019 | AnaptysBio | ANAB | Downgrade | Neutral (Buy) |
36.16 (23.12) |
-36.06% | Details | |
| 11/8/2019 | Ra Pharma | RARX | Downgrade | Neutral (Buy) |
46.90 (48.00) |
2.35% | Details | |
| 11/7/2019 | GW Pharma | GWPH | Maintain | Buy (N/A) |
|
Details | ||
| 10/23/2019 | Biogen | BIIB | Upgrade | Buy (Neutral) |
281.87 (211.93) |
-24.81% | Details | |
| 10/16/2019 | Axsome Therapeutics | AXSM | New Coverage | Buy (N/A) |
20.63 (24.46) |
18.57% | Details | |
| 9/23/2019 | Regeneron Pharma | REGn | Upgrade | Buy (Neutral) |
295.87 (612.49) |
107.01% | Details | |
| 9/20/2019 | Xenon Pharmaceuticals | XENE | New Coverage | Buy (N/A) |
9.23 (31.00) |
235.86% | Details | |
| 8/8/2019 | Global Blood Therapeutics | GBT | Maintain | Buy (N/A) |
|
Details | ||
| 7/30/2019 | Neurocrine Bio. | NBIX | Maintain | Neutral (N/A) |
|
Details | ||
| 6/27/2019 | Zogenix, Inc. | ZGNX | Upgrade | Buy (Neutral) |
39.41 (15.64) |
-60.31% | Details | |
| 6/5/2019 | Inflarx NV | IFRX | Downgrade | Neutral (Buy) |
37.29 (0.78) |
-97.91% | Details | |
| 6/5/2019 | Neurocrine Bio. | NBIX | New Coverage | Neutral (N/A) |
82.16 (98.24) |
19.57% | Details | |
| 6/5/2019 | resTORbio Inc. | TORC | New Coverage | Buy (N/A) |
6.97 (7.95) |
14.06% | Details | |
| 5/7/2019 | GW Pharma | GWPH | Maintain | Buy (N/A) |
|
Details | ||
| 4/9/2019 | Zogenix, Inc. | ZGNX | Downgrade | Neutral (Buy) |
51.85 (26.68) |
-48.54% | Details | |
| 4/9/2019 | Zogenix, Inc. | ZGNX | Downgrade | Neutral (Buy) |
52.00 (39.41) |
-24.21% | Details | |
| 3/22/2019 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/21/2019 | Biogen | BIIB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/20/2019 | Sage Therapeutics | SAGE | Maintain | Buy (N/A) |
|
Details | ||
| 2/22/2019 | Inflarx NV | IFRX | New Coverage | Buy (N/A) |
32.78 (37.29) |
13.76% | Details | |
| 2/22/2019 | GW Pharma | GWPH | New Coverage | Buy (N/A) |
145.88 (218.96) |
50.1% | Details | |
| 2/22/2019 | Global Blood Therapeutics | GBT | New Coverage | Buy (N/A) |
50.55 (31.79) |
-37.11% | Details | |
| 2/22/2019 | Agile Therapeutics | AGRX | New Coverage | Buy (N/A) |
0.96 (1.15) |
19.79% | Details | |
| 2/22/2019 | AnaptysBio | ANAB | New Coverage | Buy (N/A) |
65.03 (36.16) |
-44.39% | Details | |
| 2/22/2019 | Sage Therapeutics | SAGE | New Coverage | Buy (N/A) |
147.66 (33.65) |
-77.21% | Details | |
| 2/22/2019 | Zogenix, Inc. | ZGNX | New Coverage | Buy (N/A) |
47.57 (52.00) |
9.31% | Details | |
| 2/22/2019 | Alexion Pharmaceuticals | ALXN | New Coverage | Neutral (N/A) |
129.84 (182.01) |
40.18% | Details | |
| 2/22/2019 | Biogen | BIIB | Downgrade | Neutral (Buy) |
335.16 (211.93) |
-36.77% | Details | |
| 2/22/2019 | Ra Pharma | RARX | New Coverage | Buy (N/A) |
18.54 (46.90) |
152.97% | Details | |
| 2/21/2019 | Regeneron Pharma | REGN | Downgrade | Neutral (Buy) |
422.51 (295.87) |
-29.97% | Details |
